BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 9414254)

  • 1. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy.
    Kramm CM; Chase M; Herrlinger U; Jacobs A; Pechan PA; Rainov NG; Sena-Esteves M; Aghi M; Barnett FH; Chiocca EA; Breakefield XO
    Hum Gene Ther; 1997 Nov; 8(17):2057-68. PubMed ID: 9414254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment.
    Kramm CM; Rainov NG; Sena-Esteves M; Barnett FH; Chase M; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO
    Hum Gene Ther; 1996 Oct; 7(16):1989-94. PubMed ID: 8930659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
    Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
    Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene.
    Boviatsis EJ; Park JS; Sena-Esteves M; Kramm CM; Chase M; Efird JT; Wei MX; Breakefield XO; Chiocca EA
    Cancer Res; 1994 Nov; 54(22):5745-51. PubMed ID: 7954393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Herpes vector-mediated delivery of marker genes to disseminated central nervous system tumors.
    Kramm CM; Rainov NG; Sena-Esteves M; Chase M; Pechan PA; Chiocca EA; Breakefield XO
    Hum Gene Ther; 1996 Feb; 7(3):291-300. PubMed ID: 8835217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HSV vector cytotoxicity is inversely correlated with effective TK/GCV suicide gene therapy of rat gliosarcoma.
    Moriuchi S; Krisky DM; Marconi PC; Tamura M; Shimizu K; Yoshimine T; Cohen JB; Glorioso JC
    Gene Ther; 2000 Sep; 7(17):1483-90. PubMed ID: 11001368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase.
    Boviatsis EJ; Scharf JM; Chase M; Harrington K; Kowall NW; Breakefield XO; Chiocca EA
    Gene Ther; 1994 Sep; 1(5):323-31. PubMed ID: 7584098
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term survival in a rodent brain tumor model by bradykinin-enhanced intra-arterial delivery of a therapeutic herpes simplex virus vector.
    Rainov NG; Dobberstein KU; Heidecke V; Dorant U; Chase M; Kramm CM; Chiocca EA; Breakefield XO
    Cancer Gene Ther; 1998; 5(3):158-62. PubMed ID: 9622099
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined HSV-1 recombinant and amplicon piggyback vectors: replication-competent and defective forms, and therapeutic efficacy for experimental gliomas.
    Pechan PA; Herrlinger U; Aghi M; Jacobs A; Breakefield XO
    J Gene Med; 1999; 1(3):176-85. PubMed ID: 10738566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm.
    Rainov NG; Kramm CM; Aboody-Guterman K; Chase M; Ueki K; Louis DN; Harsh GR; Chiocca A; Breakefield XO
    Cancer Gene Ther; 1996; 3(2):99-106. PubMed ID: 8729908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained release of low-dose ganciclovir from a silicone formulation prolonged the survival of rats with gliosarcomas under herpes simplex virus thymidine kinase suicide gene therapy.
    Miura F; Moriuchi S; Maeda M; Sano A; Maruno M; Tsanaclis AM; Marino R; Glorioso JC; Yoshimine T
    Gene Ther; 2002 Dec; 9(24):1653-8. PubMed ID: 12457278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curative potential of herpes simplex virus thymidine kinase gene transfer in rats with 9L gliosarcoma.
    Cool V; Pirotte B; GĂ©rard C; Dargent JL; Baudson N; Levivier M; Goldman S; Hildebrand J; Brotchi J; Velu T
    Hum Gene Ther; 1996 Mar; 7(5):627-35. PubMed ID: 8845388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer gene therapy using a replication-competent herpes simplex virus type 1 vector.
    Yoon SS; Carroll NM; Chiocca EA; Tanabe KK
    Ann Surg; 1998 Sep; 228(3):366-74. PubMed ID: 9742919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene transfer into experimental brain tumors mediated by adenovirus, herpes simplex virus, and retrovirus vectors.
    Boviatsis EJ; Chase M; Wei MX; Tamiya T; Hurford RK; Kowall NW; Tepper RI; Breakefield XO; Chiocca EA
    Hum Gene Ther; 1994 Feb; 5(2):183-91. PubMed ID: 8186298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytotoxicity, apoptosis, and viral replication in tumor cells treated with oncolytic ribonucleotide reductase-defective herpes simplex type 1 virus (hrR3) combined with ionizing radiation.
    Spear MA; Sun F; Eling DJ; Gilpin E; Kipps TJ; Chiocca EA; Bouvet M
    Cancer Gene Ther; 2000 Jul; 7(7):1051-9. PubMed ID: 10917208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bystander effect-mediated therapy of experimental brain tumor by genetically engineered tumor cells.
    Namba H; Tagawa M; Iwadate Y; Kimura M; Sueyoshi K; Sakiyama S
    Hum Gene Ther; 1998 Jan; 9(1):5-11. PubMed ID: 9458237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Herpes simplex virus thymidine kinase gene therapy for rat malignant brain tumors.
    Vincent AJ; Vogels R; Someren GV; Esandi MC; Noteboom JL; Avezaat CJ; Vecht C; Bekkum DW; Valerio D; Bout A; Hoogerbrugge PM
    Hum Gene Ther; 1996 Jan; 7(2):197-205. PubMed ID: 8788170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas.
    Herrlinger U; Woiciechowski C; Sena-Esteves M; Aboody KS; Jacobs AH; Rainov NG; Snyder EY; Breakefield XO
    Mol Ther; 2000 Apr; 1(4):347-57. PubMed ID: 10933953
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purified herpes simplex thymidine kinase retroviral particles. II. Influence of clinical parameters and bystander killing mechanisms.
    Kruse CA; Lamb C; Hogan S; Smiley WR; Kleinschmidt-Demasters BK; Burrows FJ
    Cancer Gene Ther; 2000 Jan; 7(1):118-27. PubMed ID: 10678364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors.
    Pyles RB; Warnick RE; Chalk CL; Szanti BE; Parysek LM
    Hum Gene Ther; 1997 Mar; 8(5):533-44. PubMed ID: 9095405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.